Genotype-Guided Dosing of Cyclophosphamide-Based Chemotherapy: A Pharmacogenomic Study

Authors

  • Petraitiene A Department of Clinical Pharmacology, Vilnius University, Vilnius, Lithuania Author
  • Fabbri M Department of Medical Oncology, Sapienza University of Rome, Rome, Italy Author
  • Kolev Y Department of Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria Author

DOI:

https://doi.org/10.5281/zenodo.22644267

Keywords:

cyclophosphamide pharmacogenomics, CYP2B6 polymorphism, CYP2C19 genotype, GSTA1 and ALDH1A1 variants;, genotype-guided chemotherapy dosing

Abstract

Background: Cyclophosphamide is a prodrug alkylating agent used across breast cancer, lymphoma, pediatric oncology, and
hematopoietic stem cell transplantation regimens, requiring hepatic bioactivation by CYP2B6 and CYP2C19 to form the cytotoxic
effector phosphoramide mustard, balanced against detoxification by ALDH1A1 and GSTA1. Interindividual pharmacokinetic
variability is substantial, but no consensus genotype-guided dosing algorithm currently exists for this drug. Objective: This
narrative review synthesizes published pharmacogenomic evidence on cyclophosphamide metabolism and evaluates the feasibility
of genotype-guided dosing strategies to optimize efficacy and reduce toxicity. Methods: Peer-reviewed studies addressing CYP2B6,
CYP2C19, GSTA1, and ALDH1A1 polymorphisms in relation to cyclophosphamide pharmacokinetics, treatment response, and toxicity
were identified and synthesized narratively, organized around bioactivation and detoxification pharmacology, pharmacokinetic
genotype-exposure associations, genotype-outcome associations across breast cancer, pediatric oncology, lupus nephritis, and
transplantation settings, and the practical barriers to dosing translation. Findings: CYP2B6 and CYP2C19 loss-of-function variants
are repeatedly associated with reduced 4-hydroxycyclophosphamide formation and, in several cohorts, inferior treatment response,
with combined CYP2C19-CYP2B6 genotyping explaining up to 47.9 percent of exposure variability in one analysis. GSTA1 and
ALDH1A1 variants that impair detoxification are consistently linked to increased hematologic and hepatic toxicity, including a
nearly seven-fold increased odds of severe leucopenia in GSTA1*B carriers, sometimes accompanied by improved efficacy, reflecting
a genuine activation-detoxification trade-off. Autoinduction across multi-day dosing, phenoconversion from comedications,
transporter gene contributions rivaling metabolic enzyme effects, disease-context specificity, and marked interethnic differences in
CYP2C19 allele frequency collectively explain inconsistent replication across studies. Conclusions: Existing evidence supports a
biologically plausible but not yet clinically actionable pharmacogenomic basis for cyclophosphamide dosing. Prospective,
multigene, disease-context-specific validation combining germline genotyping with therapeutic drug monitoring is needed before
genotype-guided cyclophosphamide dosing can be translated into formal clinical guidance.

References

Muñiz P, Andrés-Zayas C, Carbonell D, Chicano M, Bailén R, Oarbeascoa G, Suárez-González J, Gómez Centurión I, Dorado N, Gallardo D, Anguita J, Kwon M, Díez-Martín JL, Martínez-Laperche C, Buño I (2022) Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. Frontiers in Immunology, 13:1002959, DOI:10.3389/fimmu.2022.1002959.

Dabbish E, Scoditti S, Shehata MNI, Ritacco I (2024) Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study. Journal of Computational Chemistry, 45(10):663-670, DOI:10.1002/jcc.27280.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema ADR (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics and Genomics, 18(6):515-523, DOI:10.1097/FPC.0b013e3282fc9766.

Islam MS, Akter F, Rahman MM, Rafe MR, Aziz MA, Parvin S, Mosaddek ASM, Islam MS, Akter MW (2024) Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients. Cancer Chemotherapy and Pharmacology, 94(4):507-516, DOI:10.1007/s00280-024-04700-5.

Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I (2012) Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. European Journal of Clinical Pharmacology, 68(4):389-395, DOI:10.1007/s00228-011-1134-0.

Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenetics and Genomics, 17(6):431-445, DOI:10.1097/FPC.0b013e328045c4fb.

Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE (2019) The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. British Journal of Clinical Pharmacology, 85(9):1925-1934, DOI:10.1111/bcp.14031.

Wessels AM, Flockhart DA, Carpenter JS, Radovich M, Li L, Miller KD, Sledge GW, Storniolo AM, Otte JL, Lemler SM, Schneider BP (2011) Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving neuroblastoma. Scientific Reports, 13:11770, doxorubicin and cyclophosphamide. The Breast Journal, DOI:10.1038/s41598-023-38983-0. 17(5):536-538, DOI:10.1111/j.1524-4741.2011.01144.x.

Kalra S, Kaur RP, Ludhiadch A, Shafi G, Vashista R, Kumar R, Munshi A (2018) Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array. European Journal of Clinical Pharmacology, 74(10):1291-1298, DOI:10.1007/s00228-018-2505-6.

Huitema ADR, Mathôt RAA, Tibben MM, Rodenhuis S, Beijnen JH (2001) A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thiotepa and the autoinduction of cyclophosphamide. Journal of Pharmacokinetics and Pharmacodynamics, 28(3):211-230, DOI:10.1023/A:1011543508731.

Helsby N, Yong M, Burns K, Findlay M, Porter D (2021) Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. Cancer Chemotherapy and Pharmacology, 88(3):533-542, DOI:10.1007/s00280-021-04307-0.

Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M (2024) From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Frontiers in Pharmacology, 15:1326776, DOI:10.3389/fphar.2024.1326776.

Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, de Zoysa JZ, Tingle MD (2010) The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. British Journal of Clinical Pharmacology, 70(6):844-853, DOI:10.1111/j.1365-2125.2010.03789.x.

Kim IW, Yun H, Choi B, Han N, Kim MG, Park S, Oh JM (2013) Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. European Journal of Clinical Pharmacology, 69(8):1543-1551, DOI:10.1007/s00228-013-1507-7.

Navarro SL, Pinto N, Hawkins DS, Park JR, Dilmaghani S, Rimorin C, Wurscher M, McCune JS (2024) Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4-hydroxycyclophosphamide formation in children with cancer. Cancer Chemotherapy and Pharmacology, 94(4):627-633, DOI:10.1007/s00280-024-04703-2.

Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Research, 12(3):R26, DOI:10.1186/bcr2570.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Cancer, 102(6):1003-1009, DOI:10.1038/sj.bjc.6605587.

Mangó K, Fekete F, Kiss ÁF, Erdős R, Fekete JT, Bűdi T, Bruckner E, Garami M, Micsik T, Monostory K (2023) Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with

Downloads

Published

2025-06-22